Finland Pharmaceuticals & Healthcare Q4 2018
Although we expect growth in the Finnish pharmaceutical market to slow slightly in the coming years, Finland willcontinue being be a fairly attractive destination for multinational drugmakers to operate in. Patented medicine sales are supportedby a growing pensionable population, high per capita spending and a strong intellectual property regime. However, delays anddisagreements within the government and its opponents concerning healthcare and social services reforms create a risk ofuncertainty regarding the long-term sustainability of public healthcare spending.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook